<i id='3985218734'><strike id='3985218734'><tt id='3985218734'><pre id='3985218734'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Heart attack and stroke risk calculators need revising 
Biden launches a new push to limit health care costs 
ChatGPT in medicine: STAT answers readers' burning questions 
DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed 
What does generative AI mean for health care? We asked experts 
Leqembi, other new Alzheimer’s drugs require better biomarkers 
Medical leaders decry Supreme Court decision on affirmative action 
Cancer cells are shown to suck energy source from immune cells 
Psychedelics group wrestles with new pharma identity 
Study: Pain burden is higher in Black NFL players than white ones 
Sports medicine is finally prioritizing gender equality 
Petition to FDA: Get the lead out of consumer hair dyes
Medical leaders decry Supreme Court decision on affirmative action 
STAT Readout: Today's biotech news includes Sana and Amylyx 
Moonlake's readout produced a cash windfall. Risks remain 
